Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

ClinicalTrials.gov ID: NCT02159365

Public ClinicalTrials.gov record NCT02159365. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.

Study identification

NCT ID
NCT02159365
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
84 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 7, 2014
Primary completion
Jun 29, 2016
Completion
Jul 10, 2018
Last update posted
Jul 15, 2019

2014 – 2018

United States locations

U.S. sites
29
U.S. states
12
U.S. cities
26
Facility City State ZIP Site status
Acrc/Arizona Clinical Research Center, Inc. Tucson Arizona 85715
Highland Oncology Group Fayetteville Arkansas 72703
Comprehensive Blood And Cancer Center Bakersfield California 93309
California Cancer Associates for Research and Excellence Encinitas California 92024
Compassionate Cancer Res Grp Fountain Valley California 92708
Robert A. Moss, Md Facp, Inc. Fountain Valley California 92708
Loma Linda University Cancer Center Loma Linda California 92354
Pacific Cancer Care Monterey California 93940
Ventura County Hematology-Oncology Specialists Oxnard California 93030
Wellness Oncology & Hematology West Hills California 91307
James R. Berenson, MD, Inc. West Hollywood California 90069
Rocky Mountain Cancer Centers Llp Denver Colorado 80218
Cancer Specialists Of North Florida Jacksonville Florida 32204
Center For Cancer Care & Research Lakeland Florida 33805
Baptist Health Medical Group Oncology Miami Florida 33176
Oncology Specialists,S.C Park Ridge Illinois 60068
Investigative Clinical Research Of Indiana, Llc Indianapolis Indiana 46260
Horizon Oncology Research, Inc Lafayette Indiana 47905
Clinical Research Alliance, Inc. New York New York 10021
St Francis Hospital Greenville South Carolina 29607
Greenville Health System Greenville South Carolina 29615
Texas Oncology Dallas Texas 75231
Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
Local Institution Houston Texas 77090
Cancer Centers of South Texas San Antonio Texas 78229
Blood & Cancer Center of East Texas Tyler Texas 75701
Texas Oncology-McAllen South Second Street Weslaco Texas 78596
Blue Ridge Cancer Care Blacksburg Virginia 24060
Vista Oncology Inc., PS Olympia Washington 98502

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02159365, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 15, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02159365 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →